UK markets closed

ANGLE plc (ANPCY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
6.83-0.17 (-2.43%)
At close: 12:04PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • A
    Anonymous
    Little exchange Help

    I'm looking to establish a starter position in Angle, however I'm in the US. It looks like most of the purchase options are pretty limited. I can trade through either Schwab or IBKR with some international market access but do not see AGL.L offering that I can access on either the London or AIM exchanges. I see ticker DWV which I think is Angle PLC on the Euronet but it is restricted and can't be traded out of my accounts. That leaves ANPCY the pink sheet offering in the US. The volume is miserable on the pink sheets.

    Pretty hard to establish a position.

    FL
  • A
    Anonymous
    Bought a small stake on the pink sheets. Guess I'm locked in no since the volume will have to pick up before I could ever sell. Why would I do this? I see Parasortix as having wide application in a variety of disease genomic mutation monitoring. For instance AZN is always looking for a means to monitor NSCLC patients that are developing the T790 mutation. that would render their top selling drug Tagrisso ineffective. Obtaining biopsy samples is difficult, expensive and invasive. Parasortix could provide a much more effective means for monitoring disease progression via EGFR mutations in the circulating tumors in the bloodstream.. Now extend that to breast cancer (already approved), prostate cancer, ovarian cancer and you start to get a picture for the market for for this relatively non invasive approach to monitoring disease progression monitoring. I expect that some oncology PCR companies such as Biocartis, EXAS (Genomic Health), Qiagen (already partnered on some projects) will announce partnerships or new projects in the next 6 months or so. I also, expect more color on pharma partnerships.

    The entire premium from the FDA announcement has rolled off and now AGL is entering a grind it out period where periodic study results will provide brief catalysts but the will now need to grow the business and become profitable. The price downturn and the strength of the dollar vs the pound has provided the discount I look for in this type of speculation.

    FL
  • R
    Real Immuno Investor 10
    Unfortunately another Mesothelioma Agent has failed. Dr Zauderer is investigating $sls GPs in combination with Opdivo. Early results were more promising than this large 300 patient trial. $SLS expects MSK to release a large data set of results this quarter.
    https://www.curemeso.org/2022/03/29/data-from-negative-mesothelioma-study-into-a-monoclonal-antibody-conjugate-drug-directed-at-mesothelin-just-published-in-the-lancet/
    Data comparing anetumab ravtansine, a monoclonal antibody conjugate, against vinorelbine showed no improvement in progression-free survival.
    Data comparing anetumab ravtansine, a monoclonal antibody conjugate, against vinorelbine showed no improvement in progression-free survival.
    www.curemeso.org
  • g
    gary
    if you're not in this already you haven't been paying attention.
    will change cancer diagnosis as we know it.
    on a global scale.
    1 major pharma already on board confident of approval
  • G
    George
    Why is this falling badly after the long awaited FDA approval?
  • G
    George
    Great news as ANGLE's Parsotix can identify therapeutic targets in TNBC patients. FDA clearance is the long awaited catalyst to propel the SP into stratosphere
  • E
    E
    A snippet from recent news about a breast cancer study -
    Results from this study showed that the Parsortix system was able to harvest CTCs in a greater proportion of MBC patients (64%), compared to the antibody-based system (57%), and 99% of the cancer cells recovered by the Parsortix system had preserved morphology, allowing morphological analysis, whereas less than 1% of the cells recovered by the antibody-based system had preserved morphology. In addition, samples processed using the Parsortix system were also found to be of higher purity, with fewer blood cells present in the harvest.
    The proportion of MBC patients where cancer cells could be harvested for analysis using the Parsortix system also significantly exceeded the proportion of patients where cancer cells can be recovered from metastatic sites using tissue biopsy as less than 50% of MBC patients receive a successful tissue biopsy in accordance with US National Comprehensive Cancer Network (NCCN) clinical practice guidelines due to being too sick for the invasive procedure, inaccessibility of the tumour or failed procedures.
    The authors concluded that these results, combined with its ease of use, position the Parsortix system as the optimal system for integration into a routine cytopathology laboratory.
  • E
    E
    More good news for business expansion.
    Contract secured for bespoke assay development 28/7/21
    ANGLE plc has agreed a pharma services contract with another new customer for its recently established pharma services business. ANGLE will develop immunofluorescence (IF) assays using its Parsortix® system to detect two specific protein markers expressed by circulating tumour cells (CTCs) and implicated in DNA damage repair (DDR). The new customer is a well-funded clinical stage development company with established commercialisation agreements with multiple global pharma companies. ........
    The first phase of work agreed covers the initial assay development and validation contract generating revenues of c. US$ 400,000 over a 12 month period.................
    Once developed, the new assays will remain in the ownership of ANGLE and be added to ANGLE's menu of pre-developed tests that can be offered to other pharma customers. .......
    ANGLE has established formal collaborations with world-class cancer centres and major corporates such as Abbott, Philips and QIAGEN, and works closely with leading CTC translational research customers.

    Assuming the FDA approval comes through this year, this stock will surely fly.
  • S
    StephenUK
    FDA approval for Angle’s liquid biopsy will send this rocketing. Buying before the announcement. GLA and please do your own research
  • G
    George
    When is the FDA announcing their decision on Parsofix device?
  • E
    E
    FDA approval. Great news. Now it should start to fly
  • E
    E
    In a recent announcement Angle claim that constructive discussions are still ongoing with the FDA. They expected a decision on FDA approval for Parsortix at the end of last year so an announcement should be soon.
  • E
    E
    Yesterday Angle posted news about the successful use of the Parsortix system with metastatic prostate cancer patients. That's 48 peer-reviewed publications.
  • G
    George
    *Parsotix